Suppliers / Zhejiang Changming Pharmaceutical

Zhejiang Changming Pharmaceutical

China 8 employees Updated 9 July 2026

Zhejiang Changming Pharmaceutical is an API manufacturer based in China. It holds 3 active US drug master files and 5 valid CEPs across a filed portfolio of 6 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 5 July 2024 as NAI.

3
active US DMFs
5
valid CEPs
3
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 5 July 2024 NAI US FDA
  • 17 September 2015 NAI US FDA
  • 11 January 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Tiantai, China Not on file
Taizhou, China Not on file
China, China 3006712427

What they file, and where

Molecule Regulators Docs
Enalapril EDQM, SFDA (Saudi Arabia) 2
Lisinopril EDQM, US FDA 2
Ramipril EDQM 2
Perindopril US FDA 1
Perindopril Tert-Butylamine EDQM 1
Sitagliptin US FDA 1

Also appears on these molecule pages

Enalapril API Lisinopril API Perindopril API Perindopril Tert-Butylamine API Ramipril API Sitagliptin API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Zhejiang Changming Pharmaceutical

Does Zhejiang Changming Pharmaceutical hold a US DMF or a CEP?
Zhejiang Changming Pharmaceutical holds 3 active US drug master files and 5 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Zhejiang Changming Pharmaceutical FDA-registered?
One site operated by Zhejiang Changming Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Zhejiang Changming Pharmaceutical's last inspection go?
The most recent inspection on record closed on 5 July 2024 as NAI (No Action Indicated: nothing objectionable was found). 3 inspections are on file.
Where does Zhejiang Changming Pharmaceutical manufacture?
3 registered sites are on record, in China (Tiantai, Taizhou and China). Every site is listed on this page with the register it came from.
What does Zhejiang Changming Pharmaceutical make?
6 molecules are on record against Zhejiang Changming Pharmaceutical, including Enalapril, Lisinopril, Ramipril and Perindopril. Each links through to that molecule's full manufacturer list.
Which regulators recognise Zhejiang Changming Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Changming Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 5 July 2024.

Comparable suppliers

Zhejiang Huahai Pharmaceutical shares 5 molecules Apitoria Pharma shares 3 molecules Hetero shares 3 molecules Apotex shares 3 molecules Dr Reddy's Laboratories shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates